CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells
Author
dc.contributor.author
Silva-Pavez, Eduardo
Author
dc.contributor.author
Villar, Paulina
Author
dc.contributor.author
Trigo, César
Author
dc.contributor.author
Caamaño, Esteban
Author
dc.contributor.author
Niechi, Ignacio
Author
dc.contributor.author
Pérez, Pablo
Author
dc.contributor.author
Muñoz, Juan P.
Author
dc.contributor.author
Aguayo, Francisco
Author
dc.contributor.author
Burzio, Verónica A.
Author
dc.contributor.author
Varas Godoy, Manuel
Author
dc.contributor.author
Castro, Ariel F.
Author
dc.contributor.author
Colombo, María I.
Author
dc.contributor.author
Tapia, Julio C.
Admission date
dc.date.accessioned
2019-10-15T12:23:38Z
Available date
dc.date.available
2019-10-15T12:23:38Z
Publication date
dc.date.issued
2019
Cita de ítem
dc.identifier.citation
Cell Death and Disease, Volumen 10, Issue 2, 2019,
Identifier
dc.identifier.issn
20414889
Identifier
dc.identifier.other
10.1038/s41419-019-1306-x
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/171585
Abstract
dc.description.abstract
Protein kinase CK2 is a highly conserved and constitutively active Ser/Thr-kinase that phosphorylates a large number of substrates, resulting in increased cell proliferation and survival. A known target of CK2 is Akt, a player in the PI3K/Akt/mTORC1 signaling pathway, which is aberrantly activated in 32% of colorectal cancer (CRC) patients. On the other hand, mTORC1 plays an important role in the regulation of protein synthesis, cell growth, and autophagy. Some studies suggest that CK2 regulates mTORC1 in several cancers. The most recently developed CK2 inhibitor, silmitasertib (formerly CX-4945), has been tested in phase I/II trials for cholangiocarcinoma and multiple myeloma. This drug has been shown to induce autophagy and enhance apoptosis in pancreatic cancer cells and to promote apoptosis in non-small cell lung cancer cells. Nevertheless, it has not been tested in studies for CRC patients. We show in this work that inhibition of CK2 with silmitasertib decre